Unlock stock picks and a broker-level newsfeed that powers Wall Street.

IOB - Delayed Quote EUR

Fresenius SE & Co. KGaA (0OO9.IL)

Compare
36.71
+0.03
+(0.08%)
At close: April 11 at 4:35:27 PM GMT+1

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Michael Sen CEO, Pres & Chairman of Management Board - Fresenius Management SE 2.91M -- 1968
Ms. Sara Lisa Hennicken CFO & Member of the Management Board - Fresenius Management SE 919k -- 1980
Dr. Sebastian Biedenkopf Chief Legal Officer, HR, Labor Relations Director, Risk Mgmt & Member of Mgmt. Board 1.51M -- 1964
Ms. Helen Giza Member of the Management Board - Fresenius Management SE 1.98M -- 1968
Mr. Pierluigi Antonelli Member of Management Board of Fresenius Management SE & CEO of Fresenius Kabi -- -- --
Dr. Michael Sven Moser Ph.D. Member of Management Board of Fresenius Management SE -- -- 1977
Mr. Robert Moller Member of the Management Board of Fresenius Management SE -- -- 1970
Mr. Markus Georgi Sr. VP of Investor Relations -- -- --
Matthias Link Sr. VP Corp. Communications -- -- --

Fresenius SE & Co. KGaA

Else-Kroener-Strasse 1
Bad Homburg vor der Höhe, 61352
Germany
49 6172 6080 https://www.fresenius.com
Sector: 
Healthcare
Full Time Employees: 
315,233

Description

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Corporate Governance

Fresenius SE & Co. KGaA’s ISS Governance QualityScore as of October 1, 2023 is 2. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 1; Compensation: 2.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 7, 2025 at 6:30 AM UTC

Fresenius SE & Co. KGaA Earnings Date

Recent Events

May 18, 2023 at 12:00 AM UTC

Ex-Dividend Date